Gemini Therapeutics (NASDAQ:GMTX) Trading at $76.57

Shares of Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) were down 0% on Wednesday. The stock traded as low as $75.25 and last traded at $76.57. 520,624 shares changed hands during mid-day trading, an increase of 175% from the average daily volume of 189,291 shares. The stock had previously closed at $76.59.

Gemini Therapeutics Stock Down 0.0%

The stock’s 50 day moving average is $71.54 and its two-hundred day moving average is $71.04. The company has a market capitalization of $3.32 billion, a PE ratio of -76.57 and a beta of -0.12.

Gemini Therapeutics Company Profile

(Get Free Report)

Gemini Therapeutics was a biotechnology company focused on developing precision medicines for genetically defined forms of age-related macular degeneration (AMD), a disease that can cause vision loss. The company’s research centered on the complement system, part of the immune system implicated in AMD. Its lead clinical program, GEM103, was a recombinant form of complement factor H being investigated as a potential treatment for geographic atrophy, an advanced form of dry AMD. Gemini was based in Cambridge, Massachusetts, and focused on drug development rather than commercial products.

Further Reading

Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.